Subscribe

Toho Holdings Co., Ltd. (8129.T)

JPY4,008.00 +26.00 (+0.65%)
JP JPX Healthcare Drug Manufacturers - Specialty & Generic
Address 5-2-1, Daizawa 155-8655
Tokyo, JP
CEO Hiromi Edahiro
Website tohohd.co.jp
IPO 2002-12-11
ISIN JP3602600003

Explore sections of this company profile

Description

Toho Holdings Co., Ltd. serves as a leading wholesaler of pharmaceutical and healthcare products throughout Japan. Its extensive product range includes prescription and over-the-counter medications, reagents, medical devices and supplies, and health foods, in addition to offerings for preventive, clinical, community, and home-based medical and nursing care. Beyond distribution, the company provides comprehensive support services like developing and selling customer-focused software, assisting with the establishment of new medical facilities and pharmacies, delivering management consulting, offering medical assistance, and facilitating personnel recruitment. Toho Holdings also operates dispensing pharmacies, manufactures and distributes generic drugs, acts as a site management organization (SMO) to support clinical trials for various healthcare institutions, and supplies specialized software to the medical sector. Among its technological solutions are customer support systems such as ENIF for pharmaceutical ordering, ENI-Pharmacy for streamlining dispensing and prescribing processes, LXMATE HeLios for medical appointments, KAITOS for online medical consultations and medication guidance, ENIFwin for inventory control in large hospitals, the ENIFvoice series for voice-activated electronic medication history recording, and ENIF Nurse for home-visit nurse operational support, along with diverse logistics systems. The company, founded in 1948, is headquartered in Tokyo, Japan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY4,008.00 +26.00 (+0.65%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
129.4K
Beta
-0.09
Float Shares
44.11M
Free Float %
68.2%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.86% -6.14% -8.65% -10.86% -13.13% -11.22% -7.27% +54.97% +130.40% +65.51% +1,059.05%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
4,008.00
DCF (Unlevered) 13,755.31 +243.2%
DCF (Levered) 5,740.91 +43.2%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 0% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 2 -1
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
3.15
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +2.3% Q1'26: +3.9% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -8.3% Q1'26: -68.3% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +0.7% Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +1.1% Q1'26: +1.1% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +5.8% Q1'26: +5.2% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -4.9% ★ Q1'26: -5.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.44× ★ Q1'26: 0.44× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.09) × ERP
WACC = 93% × Ke + 7% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 13,573.56 Current price: 4,008.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
3 Rev. Ana.
3 EPS Ana. 		Mar 2027
2 Rev. Ana.
4 EPS Ana. 		Mar 2028
4 Rev. Ana.
4 EPS Ana. 		Mar 2029
2 Rev. Ana.
2 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
1.16T
est: 1.16T (-0.1%)
1.31T
est: 1.29T (+1.6%)
1.23T
est: 1.24T (-0.4%)
1.21T
est: 1.20T (+1.0%)
1.22T
est: 1.21T (+1.1%)
1.26T
est: 1.24T (+2.0%)
1.21T
est: 1.21T (-0.3%)
1.27T
est: 1.25T (+1.3%)
1.39T
est: 1.38T (+0.8%)
1.48T
est: 1.50T (-1.5%)
1.52T
est: 1.52T (-0.2%)
1.55T
1.54T – 1.55T
+1.6% YoY
1.58T
1.49T – 1.61T
+2.3% YoY
1.63T
1.45T – 1.70T
+3.1% YoY
1.67T
1.67T – 1.67T
+2.5% YoY
1.72T
1.62T – 1.75T
+2.6% YoY
EBITDA
17.29B
est: 23.93B (-27.7%)
35.91B
est: 26.50B (+35.5%)
20.92B
est: 25.43B (-17.8%)
25.47B
est: 24.70B (+3.1%)
22.23B
est: 24.88B (-10.7%)
23.43B
est: 25.50B (-8.1%)
10.86B
est: 24.96B (-56.5%)
19.49B
est: 25.70B (-24.2%)
19.23B
est: 28.35B (-32.2%)
25.70B
est: 37.07B (-30.7%)
24.88B
est: 37.64B (-33.9%)
38.26B
38.21B – 38.30B
+1.6% YoY
39.13B
36.97B – 39.92B
+2.3% YoY
40.34B
35.87B – 41.97B
+3.1% YoY
41.36B
41.36B – 41.36B
+2.5% YoY
42.45B
40.11B – 43.31B
+2.6% YoY
EBIT
10.02B
est: 18.31B (-45.3%)
28.62B
est: 20.28B (+41.1%)
14.24B
est: 19.46B (-26.8%)
19.02B
est: 18.90B (+0.6%)
15.79B
est: 19.04B (-17.1%)
17.59B
est: 19.51B (-9.8%)
4.06B
est: 19.10B (-78.7%)
12.53B
est: 19.67B (-36.3%)
12.82B
est: 21.69B (-40.9%)
19.18B
est: 34.25B (-44.0%)
18.80B
est: 34.77B (-45.9%)
35.34B
35.30B – 35.38B
+1.6% YoY
36.15B
34.15B – 36.87B
+2.3% YoY
37.27B
33.13B – 38.77B
+3.1% YoY
38.21B
38.21B – 38.21B
+2.5% YoY
39.22B
37.05B – 40.01B
+2.6% YoY
Net Income
13.54B
est: 11.14B (+21.4%)
21.77B
est: 14.69B (+48.2%)
14.23B
est: 12.25B (+16.1%)
14.38B
est: 11.57B (+24.3%)
13.86B
est: 10.70B (+29.6%)
16.23B
est: 14.15B (+14.7%)
4.99B
est: 5.46B (-8.6%)
13.38B
est: 9.20B (+45.4%)
13.63B
est: 13.10B (+4.1%)
20.66B
est: 22.40B (-7.8%)
19.84B
est: 19.00B (+4.4%)
19.33B
17.71B – 20.95B
+1.7% YoY
13.20B
12.93B – 19.32B
-31.7% YoY
17.66B
15.26B – 20.05B
+33.8% YoY
18.47B
17.35B – 19.60B
+4.6% YoY
20.47B
19.00B – 21.01B
+10.8% YoY
SGA
89.74B
est: 28.40B (+216.0%)
90.81B
est: 31.45B (+188.7%)
82.13B
est: 30.19B (+172.1%)
81.78B
est: 29.32B (+178.9%)
82.87B
est: 29.53B (+180.6%)
84.11B
est: 30.26B (+177.9%)
81.02B
est: 29.63B (+173.5%)
81.43B
est: 30.51B (+166.9%)
83.53B
est: 33.64B (+148.3%)
84.42B
est: 91.85B (-8.1%)
87.90B
est: 93.27B (-5.8%)
94.80B
94.67B – 94.91B
+1.6% YoY
96.95B
91.59B – 98.90B
+2.3% YoY
99.96B
88.87B – 104.00B
+3.1% YoY
102.48B
102.48B – 102.48B
+2.5% YoY
105.18B
99.37B – 107.30B
+2.6% YoY
EPS
181.82
est: 159.90 (+13.7%)
316.51
est: 210.80 (+50.1%)
207.11
est: 175.80 (+17.8%)
209.83
est: 166.00 (+26.4%)
207.71
est: 153.50 (+35.3%)
233.34
est: 203.00 (+14.9%)
70.76
est: 78.30 (-9.6%)
189.69
est: 132.00 (+43.7%)
196.69
est: 187.27 (+5.0%)
320.13
est: 328.87 (-2.7%)
313.19
est: 279.00 (+12.3%)
279.41
254.11 – 300.52
+0.1% YoY
229.56
185.49 – 277.18
-17.8% YoY
246.96
218.98 – 287.71
+7.6% YoY
265.00
248.86 – 281.14
+7.3% YoY
293.70
272.60 – 301.39
+10.8% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-13 A 4/5 4/5 4/5 4/5 3/5 3/5 4/5
2026-05-12 A 4/5 4/5 4/5 4/5 3/5 3/5 4/5
2026-05-11 A 4/5 4/5 4/5 4/5 3/5 3/5 4/5
2026-05-08 A- 4/5 4/5 3/5 4/5 3/5 3/5 4/5
2026-05-07 A- 4/5 4/5 3/5 4/5 3/5 3/5 4/5
2026-05-01 A- 4/5 4/5 3/5 4/5 3/5 3/5 4/5
2026-04-30 A- 4/5 4/5 3/5 4/5 3/5 3/5 4/5
2026-04-28 A- 4/5 4/5 3/5 4/5 3/5 3/5 4/5
2026-04-27 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-24 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-23 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-22 A- 4/5 4/5 3/5 4/5 2/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
5.23B
OE per share TTM
73.39
Owner's Yield
1.87%
Maintenance CapEx ratio
31.59%
Maint CapEx / Avg PPE
6.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 82 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 WisdomTree Japan Opportunities Fund OPPJ 0.20% 565.5K 0.58%
2 WisdomTree Japan SmallCap Dividend Fund DFJ 0.11% 418.2K 0.58%
3 iShares MSCI Japan Small Cap UCITS ETF IDJP.L 0.09% 529.5K 0.58%
4 iShares MSCI Japan Small-Cap ETF SCJ 0.09% 236.3K 0.50%
5 Schwab Fundamental International Small Company Index ETF FNDC 0.06% 1.81M 0.39%
6 Schwab International Small-Cap Equity ETF SCHC 0.05% 2.92M 0.06%
7 Avantis International Small Cap Equity ETF AVDS 0.05% 149.6K 0.30%
8 Avantis International Small Cap Value ETF AVDV 0.04% 7.18M 0.36%
9 iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ 0.04% 84.3K 0.83%
10 iShares MSCI EAFE Small-Cap ETF SCZ 0.04% 5.08M 0.40%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
2.16M
Shares Outstanding
64.70M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Aiko Noshiro Corporate Officer — —
Akira Umada Senior Executive Managing Director, Chief Operating Officer, Head of Sales & Director — male
Hiromi Edahiro President, Chief Executive Officer & Representative Director — male
Kengo Ogawa Corporate Officer — male
Makoto Kawamura Executive Corporate Officer — male
Shuzo Kono Corporate Officer & Director — male
Takashi Kobayashi Corporate Officer — —
Takeo Matsutani Executive Managing Director, Chief Governance Officer & Director — male
Yasuo Sakae Corporate Officer & Chief Financial Officer — —
Yoshiaki Mizusawa General Manager of Administration Division & Finance — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic